ENTR1 and metabolic disease: In conclusion, SDCCAG3 exhibited a beneficial regulatory effect on lipid metabolism in the obesity model, potentially providing a novel target for treating obesity-related metabolic diseases and offering a theoretical foundation for the development of clinical therapeutics.